Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Lunn

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Free Radical Biology & Medicine|September 1, 2007
Diet-induced endogenous formation of nitroso compounds in the GI tractGunter G C Kuhnle, Giles W Story, Torsten Reda, et al.
Haematologica|January 16, 2025
Targeting the membrane-proximal domain of CD33 to maximize the efficacy of natural killer cell-based immunotherapiesSheryl Y T Lim, Frances M Cole, George S Laszlo, et al.
Carcinogenesis|October 21, 2006
The effect of haem in red and processed meat on the endogenous formation of N-nitroso compounds in the upper gastrointestinal tractJ C Lunn, G Kuhnle, V Mai, et al.
Cancers|October 26, 2024
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell DisordersSheryl Y T Lim, Jenny Huo, George S Laszlo, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Leukemia|February 20, 2020
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemiaColin D Godwin, George S Laszlo, Brent L Wood, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Leukemia|February 16, 2021
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapyColin D Godwin, George S Laszlo, Salvatore Fiorenza, et al.
Leukemia|March 22, 2025
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)Frances M Cole, George S Laszlo, Margaret C Lunn-Halbert, et al.
Circulation|February 1, 1996
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot StudyP W Serruys, H Emanuelsson, W van der Giessen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Free Radical Biology & Medicine|September 1, 2007
Diet-induced endogenous formation of nitroso compounds in the GI tractGunter G C Kuhnle, Giles W Story, Torsten Reda, et al.
Haematologica|January 16, 2025
Targeting the membrane-proximal domain of CD33 to maximize the efficacy of natural killer cell-based immunotherapiesSheryl Y T Lim, Frances M Cole, George S Laszlo, et al.
Carcinogenesis|October 21, 2006
The effect of haem in red and processed meat on the endogenous formation of N-nitroso compounds in the upper gastrointestinal tractJ C Lunn, G Kuhnle, V Mai, et al.
Cancers|October 26, 2024
Optimizing Siglec-8-Directed Immunotherapy for Eosinophilic and Mast Cell DisordersSheryl Y T Lim, Jenny Huo, George S Laszlo, et al.
Molecular Therapy. Oncology|September 3, 2024
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, et al.
Leukemia|February 20, 2020
The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemiaColin D Godwin, George S Laszlo, Brent L Wood, et al.
Leukemia|April 27, 2022
Development of [<sup>211</sup>At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Leukemia|February 16, 2021
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapyColin D Godwin, George S Laszlo, Salvatore Fiorenza, et al.
Leukemia|March 22, 2025
Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)Frances M Cole, George S Laszlo, Margaret C Lunn-Halbert, et al.
Circulation|February 1, 1996
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot StudyP W Serruys, H Emanuelsson, W van der Giessen, et al.
Pageof 3